Advanced search
Publication Cover
Renal Failure Volume 42, 2020 - Issue 1
Submit an article Journal homepage
2,246
Views
8
CrossRef citations to date
0
Altmetric
Clinical Study

Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients

Hitoshi Minakuchia Apheresis and Dialysis Center, Keio University School of Medicine, Tokyo, Japan
,
Tadashi Yoshidaa Apheresis and Dialysis Center, Keio University School of Medicine, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1626-7773
ORCID Icon,
Noriko Kaburagib Seigakai Shibuya Station Clinic, Tokyo, Japan
,
Teppei Fujinoc Seigakai Yoyogi Station Clinic, Tokyo, Japan
,
Sho Endoa Apheresis and Dialysis Center, Keio University School of Medicine, Tokyo, Japan;d Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
,
Tomoko Yamashita Takemitsub Seigakai Shibuya Station Clinic, Tokyo, Japan;c Seigakai Yoyogi Station Clinic, Tokyo, Japan
,
Norimasa Yamashitab Seigakai Shibuya Station Clinic, Tokyo, Japan;c Seigakai Yoyogi Station Clinic, Tokyo, Japan
,
Hiroshi Itohd Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
&
Mototsugu Oyaa Apheresis and Dialysis Center, Keio University School of Medicine, Tokyo, Japan;e Department of Urology, Keio University School of Medicine, Tokyo, Japan
 show all
Pages 799-806 | Received 22 Apr 2020, Accepted 22 Jul 2020, Published online: 11 Aug 2020

References

  • Hruska KA, Mathew S, Lund R, et al. Hyperphosphatemia of chronic kidney disease. Kidney Int. 2008;74:148–157.
  • Yoshida T, Yamashita M, Hayashi M. Kruppel-like factor 4 contributes to high phosphate-induced phenotypic switching of vascular smooth muscle cells into osteogenic cells. J Biol Chem. 2012;287:25706–25714.
  • Yoshida T, Yamashita M, Horimai C, et al. Smooth muscle-selective nuclear factor-κB inhibition reduces phosphate-induced arterial medial calcification in mice with chronic kidney disease. J Am Heart Assoc. 2017; 6:e007248.
  • Vervloet MG, van Ballegooijen AJ. Prevention and treatment of hyperphosphatemia in chronic kidney disease. Kidney Int. 2018;93:1060–1072.
  • Tan CC, Harden PN, Rodger RS, et al. Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate. Nephrol Dial Transplant. 1996;11:851–853.
  • Takahashi N, Shoji T, Matsubara K, et al. Effect of histamine H2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J Am Soc Nephrol. 1999;10:1090–1094.
  • Matsunaga C, Izumi S, Furukubo T, et al. Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy. Clin Nephrol. 2007;68:93–98.
  • Cervelli MJ, Shaman A, Meade A, et al. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients. Nephrology (Carlton). 2012;17:458–465.
  • Sheikh MS, Maguire JA, Emmett M, Santa Ana CA, et al. Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest. 1989;83:66–73.
  • Ross EA, Scott WE III, Odukale AA, et al. Transient acid exposure increases sevelamer HCl phosphate binding. J Pharm Sci. 2007;96:2154–2160.
  • Autissier V, Damment SJ, Henderson RA. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. J Pharm Sci. 2007;96:2818–2827.
  • Schumacher SP, Schurgers LJ, Vervloet MG, et al. Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study. Nephrology (Carlton). 2019;24:221–226.
  • Shinzato T, Nakai S, Fujita Y, et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron. 1994;67:280–290.
  • Coppolino G, Lucisano S, Rivoli L, et al. Sevelamer hydrochloride, sevelamer carbonate and lanthanum carbonate: in vitro and in vivo effects on gastric environment. Ther Apher Dial. 2015;19:471–476.
  • Yang Y, Bykadi S, Carlin AS, et al. Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets. J Pharm Sci. 2013;102:1370–1381.
  • Floege J, Covic AC, Ketteler M, et al.; PA21 Study Group. PA21 Study Group: a phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014;86:638–647.
  • Shigematsu T; Lanthanum Carbonate Research Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial. 2008;12:55–61.
  • Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36:478–487.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.